Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Temsirolimus

Temsirolimus

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Temsirolimus

48 trials tracked of Temsirolimus: 5 in phase 3 or 4.

48Trials tracked
5Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 39 Phase 1 2 Other / NA 2
  1. Phase 4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed
  2. Phase 3 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Completed
  3. Phase 3 Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects Completed
  4. Phase 3 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed
  5. Phase 3 Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib Completed
  6. Phase 2 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed
Show 42 more trials
  1. Phase 2 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  2. Phase 2 Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Completed
  3. Phase 2 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Completed
  4. Phase 2 Phase II Study of Alternating Sunitinib and Temsirolimus Completed
  5. Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
  6. Phase 2 Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Completed
  7. Phase 2 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed
  8. Phase 2 Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery Completed
  9. Phase 2 Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  10. Phase 2 Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer Completed
  11. Phase 2 Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Completed
  12. Phase 2 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Completed
  13. Phase 2 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Completed
  14. Phase 2 Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  15. Phase 2 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed
  16. Phase 2 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed
  17. Phase 2 Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer Completed
  18. Phase 2 Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma Completed
  19. Phase 2 Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  20. Phase 2 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Completed
  21. Phase 2 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed
  22. Phase 2 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed
  23. Phase 2 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed
  24. Phase 2 Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Completed
  25. Phase 2 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed
  26. Phase 2 Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Completed
  27. Phase 2 Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer Completed
  28. Phase 2 Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery Completed
  29. Phase 2 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Completed
  30. Phase 2 Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Completed
  31. Phase 2 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed
  32. Phase 2 Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy Completed
  33. Phase 2 Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer Completed
  34. Phase 2 Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
  35. Phase 2 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed
  36. Phase 2 Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma Completed
  37. Phase 2 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed
  38. Phase 2 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma Completed
  39. Phase 1 Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors Completed
  40. Phase 1 A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Completed
  41. N/A Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] Completed
  42. N/A Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.